bBHC

Do you still use animal cells to develop new drugs?

Now, use nEPS.
High throughput screening (HTS) is a popular approach to target validation as it allows the assaying of a large number of potential biological modulators against a chosen set of defined targets.
The advantage of miniaturization and automated liquid handling allows rapid, inexpensive and effective up-scaling of small scale bench top assays to large scale assay formats.
It need human cell line for HTS. The benefits of using nEPS for in vitro disease modelling, drug discovery and toxicity testing are becoming apparent as the research community finds solutions to the hurdles commonly associated with these cells. Thus, nEPS-based in vitro HTS is a tool to identify appropriate disease targets, design effective screening assays and improve toxicity testing.

https://bit.ly/2FqURgE

Efficiency of nEPS to induce pluripotency from Mesenchymal stem cell is over 90%.
To verify inducing efficiency, We have identified SSEA-4 (pluripotent stem cell marker) to analysis FACS data.
In result, positive SSEA-4 cell after the F002 compound treatment was 92.21% compared with MSC before the F002 compound treatment.

Please check below.

STRI has the appointment of the research institute to develop incurable disease treatment of stem cell from the government. https://bit.ly/2eXQBHp